KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) EBT Margin (2016 - 2025)

Nektar Therapeutics has reported EBT Margin over the past 16 years, most recently at 159.13% for Q4 2025.

  • For Q4 2025, EBT Margin fell 18313.0% year-over-year to 159.13%; the TTM value through Dec 2025 reached 281.52%, down 16041.0%, while the annual FY2025 figure was 281.52%, 16041.0% down from the prior year.
  • EBT Margin for Q4 2025 was 159.13% at Nektar Therapeutics, up from 297.04% in the prior quarter.
  • Over five years, EBT Margin peaked at 24.0% in Q4 2024 and troughed at 736.47% in Q2 2022.
  • A 5-year average of 334.8% and a median of 276.89% in 2022 define the central range for EBT Margin.
  • Biggest five-year swings in EBT Margin: crashed -29467bps in 2022 and later skyrocketed 48686bps in 2023.
  • Year by year, EBT Margin stood at 587.02% in 2021, then soared by 56bps to 256.75% in 2022, then surged by 33bps to 171.03% in 2023, then skyrocketed by 114bps to 24.0% in 2024, then tumbled by -763bps to 159.13% in 2025.
  • Business Quant data shows EBT Margin for NKTR at 159.13% in Q4 2025, 297.04% in Q3 2025, and 352.53% in Q2 2025.